Spots Global Cancer Trial Database for Understanding Mechanisms of Acquired Resistance to BIBW2992

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Understanding Mechanisms of Acquired Resistance to BIBW2992

Official Title: Understanding Mechanisms of Acquired Resistance to BIBW2992

Study ID: NCT01074177

Conditions

Non-small Cell Lung Cancer

EGFR Mutations

Interventions

BIBW 2992

Study Description

Brief Summary: In this research study we are looking to see how effective BIBW 2992 is at suppressing the development of the T790M mutation in non-small cell lung cancer (NSCLC) patients. Epidermal growth factor receptors (EGFR) are proteins found on the surface of some cancer cells that promote a growth signal. Some cancer drugs for NSCLC work to block this signal from reaching its target on the cancer cells which in turn may slow or stop the cancer from growing. However, many times patients with EGFR mutations will stop responding to these cancer drugs and develop drug-resistance because they have developed a specific EGFR mutation called T790M. BIBW 2992 may prevent the T790M mutation from becoming active and therefore slow disease progression.

Detailed Description: * Participants will take tablets of BIBW 2992 once a day during each cycle. Each cycle is 28 days (4 weeks). * Participants will come to the clinic on Day 1, 8 and 15 of Cycle 1. For Cycle 2 through 8, they will need to come to the clinic on Day 1. After Cycle 8, they will have study visits every 2 months. * The following tests and procedures will be performed at these clinic visits: physical examination, routine blood tests, research blood samples, EKG (every fourth cycle starting cycle 5), ECHO or MUGA (every fourth cycle starting cycle 5), an assessment of the tumor by CT or MRI scan (every 8 weeks). * Participants may continue to participate in this research study as long as their tumor does not grow and their disease does not worsen and they do not have any severe side effects. * Participants will have a tumor biopsy performed at the end of their participation in this study if their tumor is growing or if they have a new tumor. The purpose of this biopsy is to assess for the presence or the absence of the mutation T790M.